Michaela Bowden

TL;DR: This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF.

TL;DR: Genetic aberrances in fallopian tube lesions, ovarian cancers, and metastases from HGSOC patients are analyzed and evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian cancer, with metastases following rapidly thereafter.

TL;DR: It is shown that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 significantly enhances T- cell activation, contributing to antitumor effects in vivo, due in part to the derepression of NFAT family proteins and their target genes, critical regulators of T-cell function.

TL;DR: Early-phase data showed that administration of ipilimumab was feasible in patients with recurrent hematologic cancers after allogeneic HSCT, although immune-mediated toxic effects and GVHD occurred.

TL;DR: Dan Robinson, Eliezer M. Robinson, Andrea Sboner, Marc Schiffman, David M. Smith, Christine Brennan, Javed Siddiqui, Rohit Mehra, Yu Chen, Dana E. Rathkopf, Michael J. Morris, Stephen B. Solomon, Jeremy C. Tomlins, Kathleen A. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T.